Sublingual Immunotherapy

Sandra Y. Lin; Bryan Leatherman

doi:10.1016/j.otc.2011.03.012

Sublingual Immunotherapy

Sandra Y. Lin, Bryan Leatherman

School of Medicine

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Sublingual immunotherapy (SLIT) has been shown to be safe and efficacious in treating allergic rhinitis. It has been used in Europe for more than 20 years, and interest in the United States is increasing. SLIT has been shown to elicit immunologic changes similar to subcutaneous injection immunotherapy. SLIT may prevent new sensitizations, improve asthma control, and decrease asthma development in allergic individuals. Although differences in antigen quantification and standardization make European dosing schemes difficult to translate in the United States, several new studies suggest the range for effective dosing. Further studies will help clarify optimal dosing.

Original language	English (US)
Pages (from-to)	753-764
Number of pages	12
Journal	Otolaryngologic Clinics of North America
Volume	44
Issue number	3
DOIs	https://doi.org/10.1016/j.otc.2011.03.012
State	Published - Jun 2011

Keywords

Allergen-specific immunotherapy
Allergic rhinitis
Asthma
Subcutaneous immunotherapy
Sublingual immunotherapy

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.1016/j.otc.2011.03.012

Cite this

@article{ce0a91d590354a86a2a75a603025ff01,

title = "Sublingual Immunotherapy",

abstract = "Sublingual immunotherapy (SLIT) has been shown to be safe and efficacious in treating allergic rhinitis. It has been used in Europe for more than 20 years, and interest in the United States is increasing. SLIT has been shown to elicit immunologic changes similar to subcutaneous injection immunotherapy. SLIT may prevent new sensitizations, improve asthma control, and decrease asthma development in allergic individuals. Although differences in antigen quantification and standardization make European dosing schemes difficult to translate in the United States, several new studies suggest the range for effective dosing. Further studies will help clarify optimal dosing.",

keywords = "Allergen-specific immunotherapy, Allergic rhinitis, Asthma, Subcutaneous immunotherapy, Sublingual immunotherapy",

author = "Lin, {Sandra Y.} and Bryan Leatherman",

year = "2011",

month = jun,

doi = "10.1016/j.otc.2011.03.012",

language = "English (US)",

volume = "44",

pages = "753--764",

journal = "Otolaryngologic Clinics of North America",

issn = "0030-6665",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Sublingual Immunotherapy

AU - Lin, Sandra Y.

AU - Leatherman, Bryan

PY - 2011/6

Y1 - 2011/6

N2 - Sublingual immunotherapy (SLIT) has been shown to be safe and efficacious in treating allergic rhinitis. It has been used in Europe for more than 20 years, and interest in the United States is increasing. SLIT has been shown to elicit immunologic changes similar to subcutaneous injection immunotherapy. SLIT may prevent new sensitizations, improve asthma control, and decrease asthma development in allergic individuals. Although differences in antigen quantification and standardization make European dosing schemes difficult to translate in the United States, several new studies suggest the range for effective dosing. Further studies will help clarify optimal dosing.

AB - Sublingual immunotherapy (SLIT) has been shown to be safe and efficacious in treating allergic rhinitis. It has been used in Europe for more than 20 years, and interest in the United States is increasing. SLIT has been shown to elicit immunologic changes similar to subcutaneous injection immunotherapy. SLIT may prevent new sensitizations, improve asthma control, and decrease asthma development in allergic individuals. Although differences in antigen quantification and standardization make European dosing schemes difficult to translate in the United States, several new studies suggest the range for effective dosing. Further studies will help clarify optimal dosing.

KW - Allergen-specific immunotherapy

KW - Allergic rhinitis

KW - Asthma

KW - Subcutaneous immunotherapy

KW - Sublingual immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=79957461559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957461559&partnerID=8YFLogxK

U2 - 10.1016/j.otc.2011.03.012

DO - 10.1016/j.otc.2011.03.012

M3 - Review article

C2 - 21621059

AN - SCOPUS:79957461559

SN - 0030-6665

VL - 44

SP - 753

EP - 764

JO - Otolaryngologic Clinics of North America

JF - Otolaryngologic Clinics of North America

IS - 3

ER -

Sublingual Immunotherapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this